Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer.

Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819 (Electronic) Linking ISSN: 14777819 NLM ISO Abbreviation: World J Surg Oncol Subsets: MEDLINE

Original Publication: London : BioMed Central, 2003-

Breast Neoplasms*/diagnostic imaging ; Breast Neoplasms*/drug therapy ; Neoadjuvant Therapy*; Contrast Media ; Diffusion Magnetic Resonance Imaging ; Female ; Humans ; Magnetic Resonance Imaging ; Prognosis ; Treatment Outcome

Background: To determine the potential of the combination of DCE-MRI imaging method with DWI and serum CA125 and CA199 levels in the evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.
Methods: Sixty-five breast cancer patients who received neoadjuvant chemotherapy in our hospital from April 2016 to April 2017 were selected as research subjects. The patients received 4 courses of neoadjuvant chemotherapy. Lesions were monitored using DCE-MRI and DWI, while ELISA was used to measure the serum expression levels of the tumour markers CA125 and CA199. The patients were divided into the remission group and ineffective group based on pathological diagnosis.
Results: There were significant differences in K ep , K trans , ADC min , ADC mean , tumour volume, and serum levels of CA125 and CA199 in patients in the remission group, before and after neoadjuvant chemotherapy, and there were significant differences in post-chemotherapy values of these indexes between the remission group and the ineffective group (p < 0.01).
Conclusion: Combination of DCE-MRI diagnostic imaging with DWI can directly reflect the lesions in breast cancer patients after neoadjuvant chemotherapy. Serum levels of CA125 and CA199 levels are useful for evaluation of the impact of neoadjuvant chemotherapy on breast cancer patients, including risk of cancer cell metastasis and changes in some small lesions.
(© 2021. The Author(s).)

Am J Cancer Res. 2019 Sep 01;9(9):1982-1994. (PMID: 31598399)
Int J Gynecol Cancer. 2018 Oct;28(8):1485-1490. (PMID: 30036226)
J Surg Res. 2021 Jan;257:412-418. (PMID: 32892139)
Int J Gynecol Cancer. 2020 Apr;30(4):491-497. (PMID: 32054646)
J Med Syst. 2020 Feb 26;44(4):75. (PMID: 32103352)
Eur Urol Oncol. 2019 Sep;2(5):597-602. (PMID: 31279815)
Breast. 2019 Nov;48 Suppl 1:S44-S48. (PMID: 31839159)
J Med Case Rep. 2019 Sep 6;13(1):289. (PMID: 31488201)
Discov Med. 2019 Mar;27(148):139-152. (PMID: 31095923)
Ann R Coll Surg Engl. 2019 Sep;101(7):453-462. (PMID: 31304767)
Ann Surg Oncol. 2019 Jan;26(1):200-208. (PMID: 30374924)
Breast Cancer. 2018 May;25(3):259-267. (PMID: 29651637)
Eur J Obstet Gynecol Reprod Biol. 2019 Jun;237:93-99. (PMID: 31029972)
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942. (PMID: 33122245)
J Surg Oncol. 2020 Dec;122(8):1595-1603. (PMID: 32844445)
Eur J Radiol Open. 2020 Feb 25;7:100223. (PMID: 32140502)
Breast Cancer Res. 2019 Jun 14;21(1):73. (PMID: 31200764)
Cell Death Dis. 2020 Sep 25;11(9):804. (PMID: 32978372)
Int J Gen Med. 2020 Nov 12;13:1105-1114. (PMID: 33209053)
Invest Radiol. 2019 Feb;54(2):110-117. (PMID: 30358693)
Breast. 2020 Feb;49:74-80. (PMID: 31739125)
Maturitas. 2020 Oct;140:64-71. (PMID: 32972637)
Jpn J Clin Oncol. 2020 Dec 16;50(12):1464-1469. (PMID: 32699909)
Hum Hered. 2019;84(4-5):160-169. (PMID: 32101877)

Keywords: Breast cancer; CA125; CA199; DCE-MRI; DWI; Neoadjuvant chemotherapy

0 (Contrast Media)

Date Created: 20210919 Date Completed: 20210921 Latest Revision: 20210923

20250114

PMC8449881

10.1186/s12957-021-02398-w

34537053